ClinPhone, the global leader in clinical technology solutions, has made a new appointment to its Group Finance Management Team.
(May 16, 2005) - ClinPhone, the global leader in clinical technology solutions, has made a new appointment to its Group Finance Management Team. Scott Brown has joined the Company in the role of Chief Financial Officer and will be responsible for its overall financial management. Scott will also be tasked with setting financial goals across the Company and ensuring these are measured and reported as appropriate.
Latterly a principal for a consultancy firm specializing in implementation of strategic initiatives, Scott also previously spent five years as Assistant Director for ABN AMRO Corporate Finance, working in both the UK and Hong Kong offices. Scott brings with him a wealth of industry experience and financial knowledge gained from a career spanning 16 years. He will be working closely with the Board of Directors to co-ordinate, monitor and compile detailed, accurate and concise information regarding the Company's operational activity, business opportunity and achievement against business targets.
Scott is a commercially astute and accomplished finance professional with an established record of delivering value in business turnaround and growth situations. He is also a qualified accountant possessing exceptional technical, analytical and management skills with an ability to leverage a range of expertise in strategy, planning, operations and finance.
Steve Kent, Chief Executive Officer at ClinPhone, comments: "With his wealth of experience Scott is a welcome addition to the ClinPhone team, and we feel he will be integral in the Company's continued growth. Scott has an outstanding record dealing with key stakeholders including board level management, major customers and shareholders. He is an extremely motivated and results-orientated individual and we are very excited about the prospective impact of his appointment."
Scott holds a Bachelor of Commerce degree from the University of Western Australia and is an Associate Member of the Institute of Chartered Accountants of Australia. In late 2000 and during 2001 Scott competed in the Times Clipper Round the World Yacht Race, where the high pressure situation helped to hone his management and leadership skills.
For further information on ClinPhone's clinical trial management solutions, please visit www.clinphone.com, or alternatively email info@clinphone.com
About ClinPhone
ClinPhone Group Ltd is a specialist Clinical Technology Organization (CTO) working with the leading global biotech and pharmaceutical organizations. With its corporate headquarters in Nottingham, UK, ClinPhone is the largest and most accomplished CTO with experience in over 1300 clinical trials spanning 88 countries and 71 languages.The company's solutions enable its clients to manage their clinical trials more effectively through the use of technology. Building on its telephone and web-based randomization and medication management expertise, ClinPhone can offer a wide range of innovative products covering all aspects of a clinical trial, including Electronic Patient Reported Outcomes (ePRO), Interactive Voice and Web Response (IVR and IWR), Patient Recruitment Solutions, and Clinical Trial Management Software (CTMS).
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.